Objective: As glucagon-like peptide-1 receptor agonists lower blood circulation pressure (BP) in type 2 diabetes mellitus (T2DM), we examined BP control with regards to goals set by worldwide bodies ahead of randomization in the Liraglutide Impact and Actions in Diabetes: Evaluation of cardiovascular outcome Outcomes (Head) trial. for both SBP and DBP), despite the fact… Continue reading Objective: As glucagon-like peptide-1 receptor agonists lower blood circulation pressure (BP)